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Abstract: In the present work, 12 novel Schiff’s bases containing a thiadiazole scaffold and benzamide
groups coupled through appropriate pharmacophore were synthesized. These moieties are associated
with important biological properties. A facile, solvent-free synthesis of a series of novel 7(a–l)
N-((5-(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide was carried out under
microwave irradiation. Structures of the synthesized compounds were confirmed by IR, NMR, mass
spectral study and elemental analysis. All the synthesized hybrids were evaluated for their in vitro
anticancer activity against a panel of four human cancer cell lines, viz. SK-MEL-2 (melanoma), HL-60
(leukemia), HeLa (cervical cancer), MCF-7 (breast cancer) and normal breast epithelial cell (MCF-10A)
using 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay method. Most of
the synthesized compounds exhibited promising anticancer activity, showed comparable GI50 values
comparable to that of the standard drug Adriamycin. The compounds 7k, 7l, 7b, and 7a were found
to be the most promising anticancer agents in this study. A molecular docking study was performed
to predict the probable mechanism of action and computational study of the synthesized compounds
7(a–l) was performed to predict absorption, distribution, metabolism, excretion and toxicity (ADMET)
properties, by using QikProp v3.5 (Schrödinger LLC). The results showed the good oral drug-like
behavior of the synthesized compounds 7(a–l).
Keywords: microwave-assisted synthesis; thiadiazoles; in vitro anticancer activity; molecular
docking; ADMET
1. Introduction
Cancer is a disease in which cells grow and proliferate in an uncontrolled manner. Cancer evokes
a high level of mortality regardless of the recent advances in the development of clinically authorized
anticancer agents [1–3].
The development of resistance to chemotherapeutic agents and associated side effects are major
obstacles to effectively treating cancer [3]. Thus, it is necessary to identify and develop new anticancer
agents with improved efficacy and reduced side effects to complement the present chemotherapeutic
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strategies. Hence, further research towards the development of newer therapeutic drugs that more
effectively combat cancer is needed.
One of the potential targets for new drugs is the matrix metalloproteinases (MMPs), a group
of proteinases that have physiologic roles in degrading and remodeling the extracellular membrane.
The MMPs are over-expressed in a variety of malignant tumor types, and their over-expression
is associated with tumor aggressiveness and metastatic potential [4–8]. The specific alteration of
the MMPs observed in malignant tissues and their participation in some of the major oncogenic
mechanisms have fueled interest in the design and evaluation of MMP inhibitors as anticancer agents [9–12].
The class of organic compounds containing the azomethine (–HC=N–) group in their structure is
called imine, or alternatively a Schiff base. Schiff bases, derived mostly from a variety of heterocyclic
rings, were reported to possess a broad spectrum of pharmacological activities with a wide variety of
biological properties, and development of new chemotherapeutic Schiff bases is now attracting the
attention of medicinal chemists. They are known to exhibit a variety of potent biological activities.
Heterocyclic nucleus 1,3,4-thiadiazole constitutes an important class of compounds for new
drug development because of its interesting biological properties, which include anticancer [13],
antibacterial [14] and antifungal activity [15]. Thiadiazoles (e.g., 1,3,4-thiadiazoles) also exhibit a
number of extremely interesting spectroscopic properties. One of the very interesting spectroscopic
properties of thiadiazoles is the dual fluorescence effect [16–19]. In addition, 1,3,4-thiadiazole
compounds are excellent ligands and a good skeleton for metallo-complexes [20]. Especially,
the structure of “N–C–S” in 1,3,4-thiadiazole derivatives can work as the active center, chelate
certain metal ions in vivo and show good tissue permeability. The synthesis of novel thiadiazole
derivatives and investigation of their chemical and biological behavior have gained more importance
in recent decades [21–24]. The 1,3,4-thiadozole compounds have been reported to inhibit
MMPs [25]. Structure–activity relationship (SAR) studies have shown that thiadiazoles are selective for
stromelysin-1(MMP-3) over gelatinase-A (MMP-2) with little or no affinity for collagenase (MMP-1) [25].
The dual roles that matrix metalloproteinases appear to play in cancer growth and metastasis [26,27]
highlighted the need for studies that address a physical basis for selective inhibition of specific MMPs.
In the present work we planned to develop Schiff’s bases containing a thiadiazole ring
and benzamide groups, because of the important biological properties associated with these
groups. The coupling of these important moieties was achieved under microwave irradiation.
Microwave-induced synthesis has various advantages over conventional synthesis, such as a highly
accelerated reaction rate, reasonably good yields, a lesser solvent requirement, an eco-friendly method,
a clean heating system and controlled reaction parameters [28].
All the synthesized hybrids were evaluated for their in vitro anticancer activity against a panel of
four human cancer cell lines viz. against MCF-7 (human breast cancer cell line), HeLa (human cervical
cancer cell line), SKMEL-2 (human melanoma cancer cell line) and HL-60 (human leukemia cancer cell
line) by MTT assay using Adriamycin as the standard drug. A molecular docking study has also been
performed to support the effective binding of the compound at the active site of the enzyme. Most of
the synthesized compounds exhibited promising anticancer activity, with some compounds having
GI50 values equivalent to that of the standard drug, Adriamycin. The compounds 7k, 7l, 7b and 7a
were found to be the most promising anticancer agents in this study. All the synthesized compounds
were screened for their in silico absorption, distribution, metabolism, excretion and toxicity (ADMET)
study as well.
2. Result and Discussion
2.1. Chemistry
Herein, we report the facile synthesis of novel N-((5-(substituted methylene amino)-1,3,4-thiadiazol-
2-yl)methyl) benzamide derivatives under microwave irradiation as shown in Scheme 1. The N-((5-
(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide derivatives were synthesized
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from N-((5-amino-1,3,4-thiadiazol-2-yl)methyl) benzamide (0.01 mol) (5) and various suitable
aldehydes (6) (0.01 mol) using conventional method and microwave method, as shown in Table 1.
All the synthesized compounds were characterized by 1H-NMR, 13C-NMR, mass spectroscopy, IR and
elemental analysis.
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Scheme 1. Synthesis of N-((5-(Substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide
derivatives 7(a–l).
Table 1. Details of synthesis of N-((5-(Substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl)
benzamide derivatives 7(a–l) using conventional method and microwave method.
Entry
Conventional Method Microwave Method
Solvent Temperature ◦C Time (h) Yield (%) Time (min) Yield (%)
7a Ethanol 80–90 3.30 78 8 95
7b Ethanol 80–90 5.10 77 12 92
7c Ethanol 80–90 5.00 78 12 94
7d Ethanol 80–90 7.20 66 15 94
7e t l 80–90 7.25 52 15 92
7f Ethanol 80–90 8.00 48 18 92
7g Ethanol 80–90 5.25 76 12 95
7h Ethanol 80–90 7.30 66 15 88
7i Ethanol 80–90 8.00 68 20 86
7j t l 80–90 8. 0 48 20 88
7k Ethanol 80–90 4.15 44 10 85
7l Ethanol 80–90 4.25 56 10 84
2.2. In Vitro Anticancer Activity
The synthesized compounds 7(a–l) were evaluated for their in vitro anticancer activity against
MCF-7 (human breast cancer cell line), HeLa (human cervical cancer cell line), SKMEL-2 (human
melanoma cancer cell line) and HL-60 (human leukemia cancer cell line) cancer cell lines, as shown
in Table 2. The most active compounds 7k, 7l, 7a and 7b were tested on non-tumorigenic breast
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epithelial cell lines (MCF-10A) to find out the selectivity towards the cancer cells. The GI50 values (the
concentration required to achieve a growth inhibition of 50%) for the synthesized compounds were
determined by MTT assay method. The in vitro anticancer evaluation results and GI50 values were
listed in Table 2, and the well-known anticancer drug Adriamycin was used as positive control.
Table 2. In vitro anticancer activity of the synthesized compounds 7(a–l).
Entry
GI50 µM
MCF-7 HeLa SKMEL-2 HL-60 MCF-10A
7a 22.9 32.8 21.9 21.7 >100
7b 28.7 39.0 22.9 28.2 86.1
7c 32.4 41.1 27.5 33.3 ND
7d 36.7 52.4 34.0 40.2 ND
7e 35.2 46.8 28.1 39.6 ND
7f 38.4 49.2 30.0 37.5 ND
7g 41.0 66.1 46.4 42.4 ND
7h 46.2 71.7 49.1 48.2 ND
7i 49.0 78.0 52.6 45.8 ND
7j 51.4 78.8 55.7 49.9 ND
7k 11.7 23.8 19.6 35.5 > 100
7l 19.0 28.8 22.0 29.9 > 100
ADR < 10 < 10 < 10 < 10 ND
ADR Adriamycin standard drug used.GI50 is the concentration exhibiting 50% inhibition of the growth, as compared
to the growth of control.MCF-7 human breast cancer cell line, HeLa human cervical cancer cell line, SKMEL-2
human melanoma cancer cell line, HL-60 human leukemia cancer cell line, MCF-10A normal breast epithelial cell
lines and ND = Not determined.
The results indicated that the compounds 7k, 7l, 7a and 7b exhibited significant cancer cell growth
inhibition compared to reference standard Adriamycin against MCF-7, HeLa, SKMEL-2 and HL-60
cancer cell lines. From the in vitro anticancer activity results, it was observed that compound 7k, which
has a furan ring, was found to have the GI50 values 11.7 µM, 23.8 µM, 19.6 µM and 35.5 µM for MCF-7,
HeLa, SKMEL-2 and HL-60 cancer cell lines, respectively. Compound 7l, which has a thiophene ring,
was found to have the GI50 values 19.0 µM, 28.8 µM, 22.0 µM and 29.9 µM for MCF-7, HeLa, SKMEL-2
and HL-60 cancer cell lines, respectively. Compound 7a containing 4-Chlorophenyl substituent (MCF-7
GI50 22.9 µM, HeLa GI50 32.8 µM, SKMEL-2 GI50 21.9 µM and HL-60 GI50 21.7 µM) and compound 7b
2,4 dichloro phenyl substituent (MCF-7 GI50 28.7 µM, HeLa GI50 39.0 µM, SKMEL-2 GI50 22.9 µM and
HL-60 GI50 28.2 µM) were found to have good in vitro anticancer activity.
From the in vitro anticancer result data as shown in Table 2, the most active compounds 7k, 7l, 7a
and 7b were tested on non-tumorigenic breast epithelial cell lines (MCF-10A) to find out the selectivity
towards the cancer cells. Interestingly, compounds 7k, 7l and 7a were found to be selective towards
cancer cells, since they did not exhibit cytotoxicity (GI50 >100 µM) on MCF-10A cells. However,
compound 7b showed almost three times more selectivity for MCF-7 cancer cell lines in comparison to
the MCF-10A normal breast epithelial cell lines.
Structure-activity relationship (SAR) studies for these compounds demonstrated that electron
withdrawing groups such as chloro (7a, 7b) exhibited good in vitro anticancer activity compared to
electron donating groups. Compound 7c with 4-hydroxyphenyl substituent (MCF-7 GI50 32.4 µM,
HeLa GI50 41.1 µM, SKMEL-2 GI50 27.5 µM and HL-60 GI50 33.3 µM) was found to be more active
than compound 7e with 4-hydroxy-3-methoxyphenyl substituent (MCF-7 GI50 35.2 µM, HeLa GI50
46.8 µM, SKMEL-2 GI50 28.1 µM and HL-60 GI50 39.6 µM) and compound 7f with 4-hydroxy-3-ethoxy
phenyl substituent (MCF-7 GI50 38.4 µM, HeLa GI50 49.2 µM, SKMEL-2 GI50 30.0 µM and HL-60 GI50
37.5 µM). Replacement of the phenyl group in the parent compound by furan ring in 7k and thiophene
ring in 7l showed a significant increase in the in vitro anticancer activity in comparison to the standard
drug Adriamycin. From SAR, it can be considered that compounds containing electron-donating polar
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groups such as 7c, 7d, 7e, 7f, 7g, 7h, 7i and 7j are less active in comparison to the electron-withdrawing
groups, such as 7a and 7b. It is also clear that the replacement of the phenyl ring with the furan ring
(7k) and thiophene ring (7l) significantly increased the in vitro anticancer activity. Compounds having
large, bulky di-substituted and tri-substituted groups on phenyl ring showed a decrease in in vitro
anticancer activity (for example, 7e and 7f) than compounds having less bulky substituents on phenyl
ring, such as 7a and 7b. Compounds 7k and 7l showed significantly good in vitro anticancer activity
in comparison to the standard anticancer drug Adriamycin against MCF-7, HeLa, SKMEL-2 and HL-60
cancer cell lines and thus can be developed as anticancer agents in the future.
2.3. Molecular Docking
Unregulated or over-expressed matrix metalloproteinases (MMPs), including stromelysin,
collagenase and gelatinase, were implicated in several pathological conditions, including arthritis
and cancer. The 1,3,4-thiadozole compounds have been reported to inhibit selectively fibroblast
stromelysin-1 [24,29]. In order to predict the binding affinity of our newly synthesized N-((5-
(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7(a–l) derivatives into the
binding site of fibroblast stromelysin-1, we decided to carry out a molecular docking study. The docking
results indicated that compounds were held in the active pocket by a combination of various hydrogen
bonds and hydrophobic interactions with fibroblast stromelysin-1. The docking results revealed that
the compound 7k had the highest binding interaction with fibroblast stromelysin-1, with a docking
score of −7.56, as shown in Table 3.
On the basis of the docking results, it was found that compounds 7k, 7l, 7a and 7b had good
potential to inhibit fibroblast stromelysin-1, which will be the probable mechanism of these derivatives
for their anticancer activity. The docking score of all the synthesized derivatives is shown in Table 3.
Table 3. Docking score of all the synthesized derivatives 7(a–l).
Compound Docking Score Compound Docking Score
7a −6.61 7h −6.33
7b −6.56 7i −6.61
7c −5.93 7j −5.10
7d −5.82 7k −7.56
7e −5.84 7l −7.32
7f −5.66 ADR −4.33
7g −5.26
From the docking analysis, it was observed that compound 7b showed hydrogen bond interaction
with amino acid residue Tyr223; while on the other hand, hydrogen bonding is seen with amino
acid residues Ala165 and Ala167 in compound 7k (Figure 1). The hydrophobic interactions such
as pi-pi stacking and pi-pi cation between compounds and surrounding hydrophobic amino acid
residues of enzymes helped to stabilize the complex structure and thus enhanced the binding affinity
of compounds towards fibroblast stromelysin-1 (Figure 1). It was also seen that the –CONH group of
both compounds 7b and 7k makes a metal coordination with zinc ion present in the active site of the
enzyme, which is a probable mechanism of inhibition of fibroblast stromelysin-1.
Molecules 2017, 22, 995 6 of 14




Figure 1. Docking pose of: (a) Compound 7b; (b) Compound 7k in the active pocket of Fibroblast 
stromelysin-1. The pink-colored dotted line indicates H-bond, the cyan-colored dotted line indicates 
pi-pi stacking interaction, and the green-colored dotted line indicates pi-pi cation interaction between 
ligand and enzyme. 
2.4. In Silico ADMET Prediction 
The absorption, distribution, metabolism, excretion and toxicity (ADMET) play a critical role in 
helping to optimize the pharmacokinetic properties of new drugs, as it increases their success rate. 
Thus the prediction of the ADMET parameters prior to experimental studies is one of the most 
important aspects of both drug discovery and development of the drug molecule. The prediction of 
Lipinski’s rule-of-five was performed to indicate whether a chemical compound could be an orally 
active drug in humans. The prediction of ADMET properties was performed for all compounds and 
is shown in Table 4. It was observed that all the compounds exhibited a good predicted percentage of oral 
absorption (% ABS) ranging from 75–100%. The predicted aqueous solubility (Log S) (S in mol/L) and 
predicted partition coefficient (Log Po/w) value for all compounds was found within the range of 
−6.1 to −4.2 and 3.91–5.34 respectively, and thus is a probable reason for the predicted good percentage of 
oral absorption for all compounds. The efficiency and distribution of a drug may be affected by the 
degree to which it binds to the proteins present within the blood plasma. The log Khsa parameter is 
used for the prediction of binding to the human serum albumin. All compounds showed predicted 
log Khsa value ranges between −0.2 and 0.19, which indicated that a significant proportion of the 
compounds are likely to circulate freely in the blood stream and can reach the drug target sites. 
7b 
7k 
Figure 1. Docking pose of: (a) Compound 7b; (b) Compound 7k in the active pocket of Fibroblast
stromelysin-1. The pink-colored dotted line indicates H-bond, the cyan-colored dotted line indicates
pi-pi stacking interaction, and the green-colored dotted line indicates pi-pi cation interaction between
ligand and enzyme.
2.4. In Silico ADMET Prediction
The absorption, distribution, metabolism, excretion and toxicity (ADMET) play a critical role
in helping to optimize the pharmacokinetic properties of new drugs, as it increases their success
rate. Thus the prediction of the ADMET parameters prior to experimental studies is one of the most
important aspects of both drug discovery and d velopment of the drug m lecule. The prediction of
Lipinski’s rule-of-five was performed t indicate whether a chemical compound uld be an orally
active drug in humans. The pr diction of ADMET roperties was perf rmed for all compounds and is
shown in Table 4. It was observed that all the com ounds exhibited a good predicted percentage of oral
absorption (% ABS) ranging from 75–100%. The predicted aqueous olubility (Log S) (S in mol/L) and
predicted partition coefficient (Log Po/w) value for all compounds was found within the range of −6.1
to −4.2 and 3.91–5.34 respectively, and thus is a probable reason for the predicted good percentage of
oral absorption for all compounds. The efficiency and distribution of a drug may be affected by the
degree to which it binds to the proteins present within the blood plasma. The log Khsa parameter is
used for the prediction of binding to the human serum albumin. All compounds showed predicted
log Khsa value ranges between −0.2 and 0.19, which indicated that a significant proportion of the
compounds are likely to circulate freely in the blood stream and can reach the drug target sites.
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Table 4. In silico physicochemical pharmacokinetic parameters important for good oral bioavailability of the synthesized compounds 7(a–l).
Entry M.W a LogP o/w
b
(−2.0–6.5) n-ON





h #Meta i (1–8) Log HERG
j
Below−5
Lipinski Rule of 5
(≤1)
7a 356.8 4.82 5.5 1 76.2 0.31 −5.8 98 2 −6.8 0
7b 391.2 5.34 5.5 1 74.4 0.37 −6.1 99 2 −6.6 0
7c 338.3 5.18 6.2 2 98.4 0.02 −4.7 89 3 −6.7 0
7d 338.3 5.17 6 2 98.2 0.03 −4.3 88 3 −6.5 0
7e 368.4 5.27 7.2 1 133.3 −0.04 −4.7 75 3 −6.6 0
7f 382.4 5.09 7 2 105.7 0.16 −5.5 91 4 −6.9 0
7g 352.4 4.91 6.2 1 83.9 0.16 −5.1 100 3 −6.7 0
7h 382.4 5.20 7 1 89.0 0.19 −5.4 100 4 −6.7 0
7i 412.2 4.05 7.7 1 95.4 0.17 −5.4 100 5 −6.5 0
7j 412.2 4.08 7.7 1 97.6 0.19 −5.6 100 5 −6.6 0
7k 312.3 3.91 6 1 84.7 −0.11 −4.0 94 3 −6.3 0
7l 328.4 4.11 5 1 85.6 −0.21 −4.2 95 3 −6.2 0
a Molecular weight of the molecule; b Predicted octanol-water partition coefficient (log Po/w) (−2.0 to 6.5); c n-ON number of hydrogen bond acceptors ≤10; d n-OHNH number of
hydrogen bonds donors ≤5; e Polar surface area (PSA) (7.0–200.0); f Logarithm of predicted binding constant to human serum albumin (log Khsa) (−1.5 to 1.2); g Logarithm of aqueous
solubility(Log S) (−6 to 0.5); h Percentage of human oral absorption (% ABS) (>80% is high, <25% is poor); #Metabolism I (1–8); j Predicted IC50 value for blockage of HERG K+ channels
(log Khsa) (−1.5 to 1.2).
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Human ether-a-go-go related gene (HERG) encodes a potassium ion (K+) channel that is
implicated in the fatal arrhythmia known as torsade de pointes, or the long QT syndrome [30]. The HERG
K+ channel, which is best known for its contribution to the electrical activity of the heart that
coordinates the heart’s beating, appears to be the molecular target responsible for the cardiac toxicity of
a wide range of therapeutic drugs [31]. HERG has also been associated with modulating the functions
of some cells of the nervous system, and with establishing and maintaining cancer-like features in
leukemic cells [32]. Thus, HERG K+ channel blockers are potentially toxic and the predicted IC50
values often provide reasonable predictions for the cardiac toxicity of drugs in the early stages of drug
discovery [33]. Thus, based on predicted log HERG values, none of the synthesized compounds 7(a–l)
were found to be toxic in nature. Similarly, it was also seen that none of the compounds have violated
the Lipinski rule-of-five (M.W < 500, l Log Po/w<5, n-ON < 10, n-OHNH < 5). The overall ADMET
prediction studies thus clearly suggested that all synthesized compounds have good pharmacokinetic
properties and can be developed as good oral drugs in the future.
3. Materials and Methods
3.1. General Information
All the chemicals used for synthesis were of Merck, Sigma, Research lab, Qualigens make and
Himedia. The reactions were carried out by conventional method and in synthetic microwave oven
(Milestone micro synth). Melting points were determined in open capillaries using melting point
apparatus and are uncorrected. All the reactions were performed in oven-dried glassware. Phosphorus
oxychloride was used by distilling under reduced pressure. The synthetic protocol employed for the
synthesis of N-((5-(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide derivatives
7(a–l) is presented in Scheme 1. The purity of the synthesized compounds was checked by TLC, and
melting points were determined in open capillary tubes and are uncorrected. The NMR spectra of the
final titled compounds N-((5-(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide
were recorded on Brucker Advance II (400 MHz), and Infrared (IR) spectra were recorded for the
compounds on JASCO FTIR (PS 4000, JASCO, Tokyo, Japan) using KBr pallet. The mass spectra were
recorded on a Waters Micro Mass (ZQ 2000 spectrometer, UK). Elemental analyses were done with a
FLASHEA 112 Shimadzu’ analyzer (Mumbai, Maharashtra, India) and all analyses were consistent
(within 0.4%) with theoretical values.
3.1.1. Step I: General Process for Synthesis of 2-Benzamidoacetic Acid [34]
The first step involved dissolving 0.33 mol of 2-aminoacetic acid (2) in 10% NaOH solution
contained in a conical flask. To this solution, 0.38 mol of benzoyl chloride (1) was added in five
portions and shaken vigorously until the chloride reacted. The solution was transferred to a beaker
containing crushed ice and dil. HCl was added until the solution was acidic to congo red paper.
The resulting crystalline solid was collected and boiled with 10 mL of CCl4 for 10 min. The product
was filtered and washed with CCl4. The solid product obtained was dried and recrystallized from
ethanol. The melting point and yield were recorded.
3.1.2. Step II: General Procedure for Synthesis of N-((5-Amino-1,3,4-thiadiazol-2-yl)methyl)
Benzamide [35]
Next, 2-benzamidoacetic acid (3) (0.05 mol) was refluxed with thiosemicarbazide (4) (0.05 mol)
and phosphorus oxychloride (15 mL) for 1 h. The mixture was cooled and diluted with water (90 mL)
and again refluxed for 4 h. Then the mixture was filtered, and the filtrate was basified with potassium
hydroxide solution. The precipitate was filtered off and recrystallized from ethanol.
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3.1.3. Step III: General procedure for synthesis of (E)-N-((5-(substituted methyleneamino)-1,3,4-
thiadiazol-2-yl)methyl) benzamide 7(a–l)
A. Conventional method [36]
Equimolar quantities of N-((5-amino-1,3,4-thiadiazol-2-yl)methyl) benzamide (0.01 mol) (5) and
various suitable aldehydes (6) (0.01 mol) were refluxed in the presence of glacial acetic acid (0.02 mol)
in absolute ethanol (25 mL) for 3–8 h. The completion of the reaction was monitored by Thin Layer
Chromatography (TLC). The reaction mixture was concentrated and cooled. The obtained solid
was filtered and dried. The product was recrystallized from ethanol. The melting point and yield
were recorded.
B. Microwave-assisted method [37]
Solvent-free synthesis of Schiff’s bases was achieved by cyclo addition of various suitable
aldehydes (6) (0.01 mol) and N-((5-amino-1,3,4-thiadiazol-2-yl)methyl) benzamide (5) (0.01 mol) in the
presence of a catalytic amount of glacial acetic acid under microwave irradiation at 250 W for 8–20 min,
as shown in Scheme 1. The completion of the reaction was monitored by TLC. The synthesized products
were recrystallized from ethanol. The same compounds were also synthesized using conventional
approach. A comparative study in terms of yield and reaction period has been reported for both
microwave-assisted and conventional methods. The conventional method required about 3–8 h, while
the microwave-irradiation method required only 8–20 min, as shown in Table 1.
2-Benzamidoacetic acid 3. Yield: 95%; m.p.: 187–190 ◦C;IR (KBr νmax in cm−1): 3350.41 (NH), 3179.92
(OH), 2970.76 (C=H), 1810.26 (C=O of amide), 1725.01 (C=O of carboxylic acid); 1H-NMR (DMSO) δ
ppm: 3.84 (s, 2H, CH2), 7.77–8.00 (m, 5H), 8.05 (s, 1H, NH), 11.35 (s, 1H, OH); 13C-NMR (DMSO) δ
ppm: 41.34,127.31, 127.87, 128.00, 128.61, 132.89, 134.23, 167.87, 172.11; m/z: 179.06 (100.0%), 180.06
(10.3%), 181.06 (1.1%); Anal. Calcd. For C9H9NO3: C, 60.33; H, 5.06; N, 7.82; O, 26.79. Found: C, 60.35;
H, 5.08; N, 7.80; O, 26.76.
N-((5-Amino-1,3,4-thiadiazol-2-yl)methyl) benzamide 5. Yield: 92%; m.p.: 218–220 ◦C; IR (KBr νmax in
cm−1): 3360.45 (NH2), 3000 (C-H aromatic), 2970.76 (C=H), 1810.26 (C=O of amide), 1454.55 (CH of
CH2); 1H-NMR (DMSO) δ ppm: 3.45 (s, 2H, CH2), 6.89 (s, 2H, NH2), 7.70–8.00 (m, 5H), 8.05 (s, 1H, NH);
13C-NMR (DMSO) δ ppm: 39.11,127.26, 127.69, 128.42, 128.76, 132.11, 134.21, 161.66, 167.89, 168.00;
m/z: 234.06 (100.0%), 235.06 (11.8%), 236.05 (4.5%), 235.05 (1.5%); Anal. Calcd. For C10H10N4OS: C,
51.27; H, 4.30; N, 23.91; S, 13.69. Found: C, 51.29; H, 4.33; N, 23.89; S, 13.65.
(E)-N-((5-(4-Chlorobenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7a. Yield: 95%; m.p.:
126–128 ◦C; IR (KBr νmax in cm−1): 3355.41 (NH), 2970.76 (C=H), 1810.26 (C=O of amide), 1454.50
(CH of CH2); 1H-NMR (DMSO) δ ppm: 3.42 (s, 2H, CH2), 6.69–5.21 (m, 9H), 8.21 (s, 1H, NH), 10.33
(s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 39.11,127.36, 127.34, 127.51, 128.78, 128.98, 130.00, 130.63,
131.22, 133.23, 134.34, 134.51, 136.67, 160.00, 167.89, 168.00; m/z: 356.05 (100.0%), 358.05 (37.1%), 357.05
(20.7%), 359.05 (7.1%), 358.06 (1.6%), 360.04 (1.5%); Anal. Calcd. For C17H13ClN4OS: C, 57.22; H, 3.67;
Cl, 9.94; N, 15.70; S, 8.99. Found: C, 57.24; H, 3.69; Cl, 9.97; N, 15.68; S, 8.98.
(E)-N-((5-(2,4-Dichlorobenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7b. Yield: 92%;
m.p.: 112–114 ◦C; IR (KBr νmax in cm−1): 3352.41 (NH), 2975.76 (C=H), 1818.26 (C=O of amide), 1457.55
(CH of CH2); 1H-NMR (DMSO) δ ppm: 3.45 (s, 2H, CH2), 6.69–5.21 (m, 8H), 8.29 (s, 1H, NH), 10.33
(s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 40.11,127.36, 127.34, 127.51, 128.68, 128.98, 130.00, 130.53,
131.22, 133.13, 134.39, 134.41, 136.77, 161.00, 168.89, 169.00; m/z: 390.01 (100.0%), 392.01 (68.9%), 391.01
(20.7%), 393.01 (13.2%), 394.00 (13.1%), 395.01 (2.5%), 392.02 (1.8%), 394.01 (1.5%), 393.00 (1.0%); Anal.
Calcd. For C17H12Cl2N4OS: C, 52.18; H, 3.09; Cl, 18.12; N, 14.32; S, 8.20. Found: C, 52.19; H, 3.11; Cl,
18.14; N, 14.30; S, 8.22.
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(E)-N-((5-(4-Hydroxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7c. Yield: 94%; m.p.:
118–120 ◦C; IR (KBr νmax in cm−1): 3500.92 (OH), 3350.41 (NH), 2970.76 (C=H), 1810.26 (C=O of amide),
1458.50 (CH of CH2); 1H-NMR (DMSO) δ ppm: 3.44 (s, 2H, CH2), 5.43 (s,1H, OH), 6.69–5.20 (m, 9H),
8.21 (s, 1H, NH), 10.34 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 40.12,115.80, 116.19, 121.93, 125.20,
128.96, 129.41, 131.90, 134.60, 156.36, 163.36, 165.05, 168.54, 190.00; m/z: 338.08 (100.0%), 339.09 (18.6%),
340.08 (4.8%), 339.08 (2.3%), 340.09 (2.2%); Anal. Calcd. For C17H14N4O2S: C, 60.34; H, 4.17; N, 16.56; S
9.48. Found: C, 60.36; H, 4.19; N, 16.53; S, 9.45.
(E)-N-((5-(2-Hydroxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7d. Yield: 94%; m.p.:
106–108 ◦C; IR (KBr νmax in cm−1): 3500.90 (OH), 3350.58 (NH), 2970.66 (C=H), 1811.16 (C=O of amide),
1454.55 (CH of CH2); 1H-NMR (DMSO) δ ppm: 4.12 (s, 2H, CH2), 5.38 (s, 1H, OH), 7.02–7.71 (m, 4H),
7.81–8.10 (m, 5H), 8.16 (s, 1H, NH), 9.91 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 40.03,118.82,
120.52, 121.46, 126.89, 127.45, 127.91, 128.17, 129.80, 131.00, 132.41, 135.51, 160.55, 160.99, 169.09,
170.11; m/z: 338.08 (100.0%), 339.09 (18.6%), 340.08 (4.8%), 339.08 (2.3%), 340.09 (2.2%); Anal. Calcd.
For C17H14N4O2S: C, 60.34; H, 4.17; N, 16.56; S, 9.48. Found: C, 60.36; H, 4.19; N, 16.53; S, 9.50.
(E)-N-((5-(4-Hydroxy-3-methoxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7e. Yield:
92%; m.p.: 124–126 ◦C; IR (KBr νmax in cm−1): 3500.90 (OH), 3350.31 (NH), 2971.76 (C=H), 1810.16
(C=O of amide), 1455.55 (CH of CH2); 1H-NMR (DMSO) δ ppm: 3.83 (s, 3H, OCH3), 4.10 (s, 2H, CH2),
5.35 (s, 1H, OH), 6.93 (d, J = 8.40 Hz,1H), 7.34 (d, J = 8.41 Hz,1H), 7.52 (s, 1H), 7.70–8.08 (m, 5H), 8.19 (s,
1H, NH), 10.00 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 39.87, 56.17, 113.17, 118.16, 122.15, 126.81,
127.01, 127.76, 128.28, 129.98, 130.16, 135.09, 149.71, 152.09, 159.99, 167.71, 169.18; m/z: 368.09 (100.0%),
369.10 (19.8%), 370.09 (4.8%), 370.10 (2.6%), 369.09 (2.3%); Anal. Calcd. For C18H16N4O3S: C, 58.68; H,
4.38;N, 15.21;S 8.70. Found: C, 58.70; H, 4.39; N, 15.19; S, 8.72.
(E)-N-((5-(3-Ethoxy-4-hydroxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7f. Yield:
92%; m.p.: 130–132 ◦C; IR (KBr νmax in cm−1): 3500.90 (OH), 3350.31 (NH), 2971.76 (C=H), 1810.16
(C=O of amide), 1457.55 (CH of CH2); 1H-NMR (DMSO) δ ppm: 1.32 (t, 3H, CH3), 4.09 (q, 2H, CH2),
4.46 (s, 2H, CH2), 5.35 (s, 1H, OH), 6.91–7.52 (m, 3H, CH), 7.63-8.09 (m, 5H, CH), 8.13 (s, 1H, NH), 10.00
(s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 14.87, 39.99, 64.57, 112.38, 116.59, 122.34, 127.00, 128.19,
128.88, 130.70, 132.55, 134.47, 148.83, 151.88, 161.66, 168.78; m/z: 382.11 (100.0%), 383.11 (22.9%), 384.11
(5.6%), 384.12 (2.1%); Anal. Calcd. For C19H18N4O3S: C, 59.67; H, 4.74; N, 14.65; S 8.38. Found: C,
59.69; H, 4.76; N, 14.61; S, 8.39.
(E)-N-((5-(4-Methoxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7g. Yield: 95%; m.p.:
116–118 ◦C; IR (KBr νmax in cm−1): 3352.18 (NH), 2971.66 (C=H), 1810.17 (C=O of amide), 1454.55 (CH
of CH2); 1H-NMR (DMSO) δ ppm: 3.83 (s, 6H, OCH3), 4.19 (s, 2H, CH2), 7.06 (d, J = 8.40 Hz,1H), 7.16
(d, J = 8.41 Hz,1H), 7.60–8.06 (m, 7H), 8.17 (s, 1H, NH), 10.00 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm:
40.00, 55.89, 114.01, 114.45, 127.03, 127.52, 127.97, 128.01, 128.89, 130.71, 131.91, 132.96, 135.01, 161.00,
163.09, 169.99, 170.13; m/z: 352.10 (100.0%), 353.10 (21.8%), 354.10 (5.4%), 354.11 (1.8%); Anal. Calcd.
For C18H16N4O2S: C, 61.35; H, 4.58; N, 15.90; S, 9.10. Found: C, 61.38; H, 4.59; N, 15.88; S, 9.13.
(E)-N-((5-(3,4-Dimethoxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7h. Yield: 88%;
m.p.: 120–122 ◦C; IR (KBr νmax in cm−1): 3352.18 (NH), 2971.66 (C=H), 1810.17 (C=O of amide),
1456.75 (CH of CH2); 1H-NMR (DMSO) δ ppm: 3.83 (s, 6H, OCH3), 4.19 (s, 2H, CH2), 6.98–7.61 (m, 3H),
7.69–8.05 (m, 5H), 8.12 (s, 1H, NH), 9.98 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 39.96, 56.11, 108.92,
111.77, 124.69, 126.96, 127.58, 127.99, 128.81, 130.66, 132.10, 134.26, 149.92, 152.10, 159.91, 169.96, 170.09;
m/z: 382.11 (100.0%), 383.11 (22.9%), 384.11 (5.6%), 384.12 (2.1%); Anal. Calcd. For C19H18N4O3S: C,
59.67; H, 4.74; N, 14.65; S 8.38. Found: C, 59.69; H, 4.76; N, 14.62; S, 8.36.
(E)-N-((5-(3,4,5-Trimethoxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7i. Yield: 86%;
m.p.: 138–140 ◦C; IR (KBr νmax in cm−1): 3350.18 (NH), 2972.66 (C=H), 1810.17 (C=O of amide),
1456.87 (CH of CH2); 1H-NMR (DMSO) δ ppm: 3.85 (s, 9H, OCH3), 4.19 (s, 2H, CH2), 6.98–7.61 (m,
3H), 7.69–8.05 (m, 5H), 8.12 (s, 1H, NH), 9.98 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 39.96, 56.11,
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108.92, 111.77, 124.69, 126.96, 127.58, 127.99, 128.81, 130.66, 132.10, 134.26, 149.92, 152.10, 159.91, 169.96,
170.09; m/z: 412.12 (100.0%), 413.12 (24.1%), 414.12 (5.9%), 414.13 (2.3%), 415.12 (1.1%); Anal. Calcd.
For C20H20N4O4S: C, 58.24; H, 4.89; N, 13.58; S 7.77. Found: C, 58.27; H, 4.91; N, 13.54; S, 7.79.
(E)-N-((5-(2,4,5-Trimethoxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7j. Yield: 88%;
m.p.: 140–142 ◦C; IR (KBr νmax in cm−1): 3350.18 (NH), 2972.66 (C=H), 1810.17 (C=O of amide),
1454.55 (CH of CH2); 1H-NMR (DMSO) δ ppm: 3.86 (s, 9H, OCH3), 4.20 (s, 2H, CH2), 6.99–7.65 (m,
3H), 7.67–8.07 (m, 5H), 8.17 (s, 1H, NH), 9.99 (s, 1H, N=CH); 13C-NMR (DMSO) δ ppm: 37.96, 55.35,
109.12, 110.97, 125.19, 126.96, 127.58, 128.99, 129.81, 131.66, 133.10, 135.26, 148.92, 153.10, 158.91, 168.96,
171.09; m/z: 412.12 (100.0%), 413.12 (24.1%), 414.12 (5.9%), 414.13 (2.3%), 415.12 (1.1%); Anal. Calcd.
For C20H20N4O4S: C, 58.24; H, 4.89; N, 13.58; S 7.77. Found: C, 58.27; H, 4.92; N, 13.55; S, 7.78.
(E)-N-((5-(Furan-2-ylmethyleneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7k. Yield: 85%; m.p.:
124–126 ◦C; IR (KBr νmax in cm−1): 3350.41 (NH), 2970.76 (C=H), 1810.26 (C=O of amide), 1456.40
(CH of CH2); 1H-NMR (DMSO) δ ppm: 3.48 (s, 2H, CH2), 6.52 (t, 1H), 6.93 (d, J = 3.40 Hz,1H), 7.65 (d,
J = 1.75 Hz, 1H), 7.80 (s, 1H, N=CH), 7.75–8.05 (m, 5H), 8.19 (s, 1H, NH); 13C-NMR (DMSO) δ ppm:
40.12, 112.26, 118.90, 126.99, 127.54, 128.04, 128.57, 131.11, 134.29, 144.48, 146.99, 150.44, 167.34, 168.09;
m/z: 312.07 (100.0%), 313.07 (18.7%), 314.06 (4.5%), 314.07 (2.0%); Anal. Calcd. For C15H12N4O2S: C,
57.68; H, 3.87; N, 17.94; S, 10.27. Found: C, 57.69; H, 3.89; N, 17.92; S, 10.29.
(E)-N-((5-(Thiophen-2-ylmethyleneamino)-1,3,4-thiadiazol-2-yl)methyl) benzamide 7l. Yield: 84%;
m.p.: 130–132 ◦C; IR (KBr νmax in cm−1): 3350.18 (NH), 2975.66 (C=H), 1815.17 (C=O of amide), 1455.67
(CH of CH2); 1H-NMR (DMSO) δ ppm: 4.46 (s, 2H, CH2), 7.17 (t, 1H, CH), 7.63–8.09 (m, 6H), 8.29 (s,
1H, NH); 13C-NMR (DMSO) δ ppm: 39.91, 127.00, 127.44, 127.99, 128.34, 128.89, 130.73, 132.77, 134.55,
142.98, 152.69, 167.98; m/z: 328.05 (100.0%), 329.05 (16.4%), 330.04 (9.1%), 329.04 (3.1%), 330.05 (2.0%),
331.04 (1.7%); Anal. Calcd. For C15H12N4O2S2: C, 54.86; H, 3.68; N, 17.06; S 19.53. Found: C, 54.88; H,
3.69; N, 17.03; S, 19.55.
3.2. In Vitro Anticancer Screening
The synthesized compounds 7(a–l) were evaluated for their in vitro anticancer activity against
MCF-7 (human breast cancer cell line), HeLa (human cervical cancer cell line), SKMEL-2 (human
melanoma cancer cell line) and HL-60 (human leukemia cancer cell line) cancer cell lines. The GI50
values (concentration required to Growth inhibition of 50%) for the synthesized compounds were
determined using the MTT assays method.
Experimental procedure for MTT assay
The stock solutions of test compounds were prepared in DMSO. After 24 h incubation, different
concentrations (2, 4, 6, 8 µM) of compounds, made by serial dilution in culture medium, were added in
48 h incubation. The final concentration of DMSO was 0.01% in each well. A separate well containing
0.01% DMSO only was run as DMSO control, which was found inactive under applied conditions.
The cell growth was determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (Sigma, St. Louis, MO, USA) reduction assay, which is based on the ability of viable cells
to reduce a soluble yellow tetrazolium salt to blue formazan crystal [38,39]. Briefly, after 48 h of
treatments, the 10 µl of MTT dye, prepared in phosphate buffered saline (PBS) was added to all
wells. The plates were then incubated for 4 h at 37 ◦C. Supernatant from each well was carefully
removed, formazon crystals were dissolved in 100 µL of DMSO and absorbance at 540 nm wavelength
was recorded and each concentration was tested in threefold. The GI50 values were determined as
concentration of compounds that inhibited cancer cell growth by 50%.
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3.3. Computational Study
Molecular Docking and In Silico ADMET Prediction
Molecular docking studies were performed in Maestro 9.1 using Glide v6.8 (Schrodinger, LLC,
New York, NY, USA). All the compounds were built using Maestro build panels and optimized to
lower energy conformers using Ligprep v3.5.9 (Schrodinger, LLC). The X-ray crystal structure of the
Fibroblast stromelysin-1 enzyme (PDB code 1USN) [21] was obtained from the protein data bank
and prepared for docking using protein preparation wizards [40]. After preparation, the hydrogen
bond network in the enzyme structure was optimized using OPLS_2005 force field. The minimization
was terminated when the energy converged or the route mean square deviation (RMSD) reached a
maximum cutoff of 0.30 Å. Grids were then defined around refined and minimized structures by
centering on ligand using default box size. The final docking studies for all the compounds were
performed using the extra-precision (XP) docking mode on generated grid of protein structure [41].
The evaluation of ligand-protein binding was done with Glide (docking) score.
The ADMET properties of lower-energy conformers of all compounds were predicted using
QikProp v3.5 (Schrödinger LLC).
4. Conclusions
In summary, a new scaffold of 12 N-((5-(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl)
benzamide derivatives 7(a–l) has been synthesized in solvent free condition under microwave
irradiation and evaluated for their potential in vitro anticancer activity on MCF-7, HeLa, SKMEL-2 and
HL-60 human cancer cell lines by MTT assay using Adriamycin as a standard drug. The compounds
7k, 7l, 7b and 7a were found to be the most promising anticancer agents in this study. The compounds
7k, 7l and 7a were found to be selective towards cancer cells, since they did not exhibit cytotoxicity
even at GI50 > 100 µM on MCF-10A normal breast epithelial cell lines. The compound 7b showed
almost three times more selectivity for the MCF-7 cancer cell lines in comparison to the MCF-10A
normal breast epithelial cell lines.
The good docking scores as well as anticancer activity of these compounds have been justified by
investigating their interaction at the active site of Fibroblast stromelysin-1, as found in the docking
studies. The ADMET studies predicted good oral drug-like behavior of the newly synthesized
derivatives. The studies presented here provide innovative agents for the development of novel
anticancer agents targeting MMPs with the goal of improving cancer care.
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